(Q43749375)

26 November 2017

Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction (English)

1 reference

26 November 2017

Karen L Hardinger

1

1 reference

26 November 2017

Candace D Wang

2

1 reference

26 November 2017

Mark A Schnitzler

3

1 reference

26 November 2017

Brent W Miller

4

1 reference

26 November 2017

Martin D Jendrisak

5

1 reference

26 November 2017

Surendra Shenoy

6

1 reference

26 November 2017

Jeffery A Lowell

7

1 reference

26 November 2017

Daniel C Brennan

8

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Transplantation

26 November 2017

1 reference

26 November 2017

2

1 reference

26 November 2017

9

1 reference

26 November 2017

867-871

1 reference

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

26 November 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Diabetic rats transplanted with adult porcine islets and immunosuppressed with cyclosporine A, mycophenolate mofetil, and leflunomide remain normoglycemic for up to 100 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Chronic allograft nephropathy: a prospective randomised trial of cyclosporin reduction with or without mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Use of leflunomide in human renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Experiences with leflunomide in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

Pharmacologically induced regression of chronic transplant rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

Chronic renal allograft rejection: no response to mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20909.X

7 January 2021

10.1034/J.1600-6143.2002.20909.X

Identifiers

DOI

1 reference

release_wrkiwgxiqrhdpjrpow5nlhk27u

26 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wrkiwgxiqrhdpjrpow5nlhk27u

24 November 2022

mapped directly with Wikidata item

1 reference